Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 6/20 | 0.41 |
| ▸ | BRAF | P15056 | 6/20 | 0.41 |
| ▸ | KDR | P35968 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27637090 | 0.83 | BRAF (0.39) | SRCBRAFKDRMAPK14TP53 | |
| SCHEMBL5005317 | 0.81 | HTT (0.42) | KMT2AHTTSRCBRAFKDR | |
| SCHEMBL5007710 | 0.81 | BRAF (0.46) | KMT2AHTTSRCBRAFKDR | |
| SCHEMBL3974032 | 0.75 | SMN1; SMN2 (0.54) | KMT2AHTTSRCBRAFKDR | |
| SCHEMBL3869440 | 0.69 | MAPT (0.79) | KMT2AHTTALDH1A1MAPTCYP2C9 | |
| SCHEMBL28757656 | 0.67 | SRC (0.40) | SRCBRAFKDRMAPTMAPK14 | |
| SCHEMBL8915404 | 0.66 | ALDH1A1 (0.49) | KMT2AHTTALDH1A1MAPTADORA1 | |
| SCHEMBL15153218 | 0.66 | MEN1 (0.48) | KMT2AALDH1A1MAPTADORA1TP53 | |
| SCHEMBL8355989 | 0.66 | SRC (0.53) | KMT2AHTTSRCBRAFKDR | |
| SCHEMBL18988298 | 0.65 | ADORA1 (0.48) | KMT2AHTTALDH1A1MAPTMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1567517-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | Bayer Pharmaceuticals Corporation (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040157904-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION | 2004-08-12 | — | — | US | disclosed |
| WO-2004050650-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050651-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050651-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | KMT2A 4310/4885HTT 1948/4885SRC 3366/4885 |
| US-20040157904-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | KMT2A 4310/4885HTT 1948/4885SRC 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.